PMID- 24828426
OWN - NLM
STAT- MEDLINE
DCOM- 20141230
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 5
DP  - 2014
TI  - Impact of response shift on time to deterioration in quality of life scores in 
      breast cancer patients.
PG  - e96848
LID - 10.1371/journal.pone.0096848 [doi]
LID - e96848
AB  - BACKGROUND: This prospective multicenter study aimed to study the impact of the 
      recalibration component of response-shift (RS) on time to deterioration (TTD) in 
      health related quality of life (QoL) scores in breast cancer (BC) patients and 
      the influence of baseline QoL expectations on TTD. METHODS: The EORTC-QLQ-C30 and 
      BR-23 questionnaires were used to assess the QoL in a prospective multicenter 
      study at inclusion (T0), at the end of the first hospitalization (T1) and, three 
      (T2) and 6 months after the first hospitalization (T3). Recalibration was 
      investigated by the then-test method. QoL expectancy was assessed at diagnosis. 
      Deterioration was defined as a 5-point decrease in QoL scores, considered a 
      minimal clinically important difference (MCID). TTD was estimated using the 
      Kaplan-Meier method. Cox regression analyses were used to identify factors 
      influencing TTD. RESULTS: From February 2006 to February 2008, 381 women were 
      included. Recalibration of breast cancer patients' internal standards in the 
      assessment of their QoL had an impact on TTD. Median TTD were significantly 
      shorter when recalibration was not taken into account than when recalibration was 
      taken into account for global health, role-functioning, social-functioning, 
      body-image and side effects of systemic therapy. Cox multivariate analyses showed 
      that for body image, when recalibration was taken into account, radiotherapy was 
      associated with a shorter TTD (HR: 0.60[0.38-0.94], whereas, no significant 
      impact of surgery type on TTD was observed. For global health, cognitive and 
      social functioning dimensions, patients expecting a deterioration in their QoL at 
      baseline had a significantly shorter TTD. CONCLUSIONS: Our results showed that RS 
      and baseline QoL expectations were associated with time to deterioration in 
      breast cancer patients.
FAU - Hamidou, Zeinab
AU  - Hamidou Z
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; Public 
      health laboratory, EA 3279-College of Medicine, Marseille, France.
FAU - Dabakuyo-Yonli, Tienhan S
AU  - Dabakuyo-Yonli TS
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; 
      Biostatistic and Quality of Life Unit, Centre Georges Francois Leclerc, Dijon, 
      France; EA 4184, College of Medicine, Dijon, France.
FAU - Guillemin, Francis
AU  - Guillemin F
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; Inserm, 
      CIC-EC, department of clinical epidemiology and evaluation, university hospital 
      of Nancy, Nancy, France.
FAU - Conroy, Thierry
AU  - Conroy T
AD  - Medical oncology department, Centre Alexis Vautrin, Nancy, France.
FAU - Velten, Michel
AU  - Velten M
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; 
      Epidemiology and public health laboratory, College of Medicine, Strasbourg, 
      France.
FAU - Jolly, Damien
AU  - Jolly D
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; 
      University hospital of Reims, Reims, France.
FAU - Causeret, Sylvain
AU  - Causeret S
AD  - Surgery department, Centre Georges Francois Leclerc, Dijon, France.
FAU - Graesslin, Olivier
AU  - Graesslin O
AD  - Gynecology and Obstetrics Department, Mother Child Institute, University hospital 
      of Reims, Reims, France.
FAU - Gauthier, Melanie
AU  - Gauthier M
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; 
      Biostatistic and Quality of Life Unit, Centre Georges Francois Leclerc, Dijon, 
      France; EA 4184, College of Medicine, Dijon, France.
FAU - Mercier, Mariette
AU  - Mercier M
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; 
      Cellular and Molecular Biology Laboratory, University hospital of Besancon, 
      Besancon, France.
FAU - Bonnetain, Franck
AU  - Bonnetain F
AD  - Quality of life and Cancer clinical research Platform, Marseille, France; 
      Methodology and quality of Life in Oncology unit (EA 3181), University hospital 
      of Besancon, Besancon, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140514
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Body Image
MH  - Breast Neoplasms/pathology/*psychology/therapy
MH  - Disease Progression
MH  - Female
MH  - Gamma Rays/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Quality of Life/*psychology
MH  - Social Adjustment
MH  - Surveys and Questionnaires
MH  - Time Factors
PMC - PMC4020802
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/05/16 06:00
MHDA- 2014/12/31 06:00
PMCR- 2014/05/14
CRDT- 2014/05/16 06:00
PHST- 2013/09/06 00:00 [received]
PHST- 2014/04/11 00:00 [accepted]
PHST- 2014/05/16 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2014/12/31 06:00 [medline]
PHST- 2014/05/14 00:00 [pmc-release]
AID - PONE-D-13-36716 [pii]
AID - 10.1371/journal.pone.0096848 [doi]
PST - epublish
SO  - PLoS One. 2014 May 14;9(5):e96848. doi: 10.1371/journal.pone.0096848. eCollection 
      2014.